Clinical trial · Interventional
Pharmacokinetics and Dynamics of Nebulized Dexmedetomidine
Pharmacokinetics and Dynamics of Nebulized Dexmedetomidine in Preschool Children Undergoing Abdominal Cancer Surgery
NCT03762785CI-TRIAL-00036451unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the aim of this study is to study the pharmacokinetics and dynamics of nebulized dexmetedomidine in children undergoing major abdominal cancer surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Cancer | Malignant Abdominal Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nebulized Dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- nebulized dexmedetomidine 2ug/kg
- description
- inhalation of dexmedetomidine in the dose of 2ug/kg by nebulization
- interventionNames
- Drug: nebulized Dexmedetomidine
- type
- ACTIVE_COMPARATOR
- label
- nebulized dexmedetomidine 3ug/kg
- description
- inhalation of dexmedetomidine in the dose of 3ug/kg by nebulization
- interventionNames
- Drug: nebulized Dexmedetomidine
Primary outcomes (1)
- measure
- pharmacokinitics of dexmedetomidine
- timeFrame
- at the basline and after the end of nebuization of the drug at 5 minutes,15 minutes,30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 7 Years
Show eligibility criteria text
Inclusion Criteria: * child aged 2-7 years * ASA I or II * scheduled for abdominal surgery * with average weight, height, normal serum albumin Exclusion Criteria: * patients with allergy to the study drug * patients with significant organ dysfunction * patients with cardiac arrhythmia * patients with congenital heart disease * use of psychotropic medication and mental retardation.
References
Publications (0)
Data not yet available
No reference posted for this study.